ProteaPex Therapeutics is developing an innovative disease modifying therapeutic to treat various conditions in companion animals. This new class of therapeutic, the Extracellular Matrix Protection Factor (ECPF), is a safe and effective peptide for animal health.
Osteoarthritis (OA) is a serious health problem in pets. This disease affects over 20% of dogs and a growing number of cats in the US. Canine osteoarthritis is a degenerative disease characterized by pain and inflammation in a dog’s joints. Age, wear and tear or prior injury can cause destruction of smooth cartilage that covers and protects the bones that form the joint leading to a painful state for the animal. Osteoarthritis is incurable, but treatments like physical therapy, weight control and the use of analgesics and corticosteroids to relieve pain and improve function can improve the dog’s life. Unfortunately long-term use of these medications can cause internal bleeding, kidney failure and in extreme cases, death. LEARN ABOUT ECPF-1
ProteaPex Therapeutics is developing an innovative disease modifying therapeutic to treat osteoarthritis in companion animals. This new class of therapeutic, the Extracellular Matrix Protection Factor, is a safe and effective intra-joint injection that reduces the pain and damage caused by osteoarthritis.
March 9, 2018
ProteaPex Therapeutics won First Place on March 9 in the Orthopedic Research Society's First Annual Business Plan Competition in New Orleans, Louisianna. They detailed the business plan for their lead therapeutic, Pexagen, an injectable osteoarthritis treatment for companion animals.
February 26, 2018
ProteaPex Therapeutics has been chosen as a top 5 finalist in the Orthopedic Research Society's Business Innovation Competition. CSO, Marina D'Angelo, will pitch to an expert panel of judges on March 9 in New Orleans.
February 26, 2018
ProteaPex Therapeutics will be the subject of a short documentary in the Thought Leadership Film Series produced by WebsEdge. The documentary will air on EBTV during the Experimental Biology Conference in San Diego this April 2018.
February 13, 2018
ProteaPex Therapeutics was awarded their third patent, COMPOSITIONS AND METHODS FOR INHIBITION OF MMP8:MMP8-SUBSTRATE INTERACTIONS for their novel therapeutic ECPF-2.
April 22, 2017
Two scientific posters detailing our ECPF therapeutics will be presented this week at the Experimental Biology meeting in Chicago, Illinois (April 22-26, 2017).
November 14, 2016
Our periodontal disease therapeutic, ECPF-2, is the subject of a proof-of-concept competition grant proposal to the University City Science Center. The winners will be announced early 2017.
Download the video (88 mb)
April 2, 2016
Three scientific posters detailing our ECPF therapeutics will be presented this week at the Experimental Biology meeting in San Diego, California (April 2-6, 2016). One of the ECPF1 presentations is a finalist for the American Association of Anatomists Undergraduate Student Poster Award.
October 30, 2015
ProteaPex Therapeutics has been invited to participate in this year's Life Science Futures Partnerships in Sciences Symposium to be held in Philadelphia,PA.
Marina D'Angelo, CSO, will present osteoarthritis animal model data of efficacy for ECPF-1 as a therapeutic and human tooth model data of efficacy of ECPF-2 as a therapeutic in stabilizing dental restoration bonding.
October 13, 2015
ProteaPex Therapeutics has been granted its second patent on the"Compositions and Methods for Inhibition of MMP:MMP-Substrate Interactions" by the US Patent Office.
ProteaPex Therapeutics has developed an innovative disease modifying therapeutic technology with applications in the treatment of post-traumatic osteoarthritis and durability of dental restorations. The family of peptide inhibitors, Extracellular Matrix Protection FactorsT (ECPF) represent a broad base of products for treatment of orthopedic, dental and wound healing health issues.
September 3, 2015
Marina D'Angelo, PhD, CSO and co-founder of ProteaPex Therapeutics, was the recent subject of a Faculty Spotlight. You can see the video here: https://www.youtube.com/watch?v=wfHkSjViPbk&list=PLPM5bObzfSrBMYVokzdNZhWL4QcwO3GBZ&index=6
May 8, 2015
Our lead OA product, ECPF-1, was recently featured on public radio in a segment on pet osteoarthritis. You can listen to it here: https://www.insidehighered.com/audio/2015/05/04/canine-osteoarthritis
March 31, 2015
ProteaPex Therapeutics participated in a platform presentation at the Experimental Biology meeting in Boston, MA entitled "Development of a Serum-free, Three Dimensional Cell Culture Model for Primary Human Articular Chondrocytes to Test Potential Therapeutics"
December 16, 2013 PATENT GRANTED TO PROTEAPEX THERAPEUTICS
ProteaPex Therapeutics has been granted a patent on the "Compositions and Methods for Inhibition of MMP13:MMP-Substrate Interactions” by the US Patent Office.
ProteaPex Therapeutics has developed an innovative disease modifying therapeutic technology to treat post-traumatic osteoarthritis PTOA, Extracellular Matrix Protection Factor™ (ECPF-1). This is a novel, safe and effective intra-articular injection that reduces the pain and damage caused by OA by targeting individual protein pairs.
In addition, using ECPF-1, ProteaPex Therapeutics is developing a broad base of products for treatment of orthopedic, periodontal and wound healing health issues.
Jeff Boily, ProteaPex's Chairman will be part of the Selection Committee panel at the 2013 Animal Health Investment Forum. The KC Animal Health Investment Forum provides a unique opportunity for venture capital funds, investment firms and animal health companies to hear from emerging companies with the newest technology.
ProteaPex Therapeutics (as ChondroPro Biosciences) won the People's Choice Award in the 2012 Wharton Business Plan Competition. More...
ProteaPex Therapeutics Presents New Designs for Fracture Non-Union Therapeutics in San Diego, CA at the American Society of Bone and Mineral Research Annual Meeting
Periodontal Disease is the same in companion animals as in humans. The earliest stage of the disease is known as gingivitis and is characterized by redness, swelling and bleeding of the gums. Most pet owners notice the bad breath of their pets but at this stage the periodontal disease is already advanced. Advanced periodontal disease is characterized by deepened pockets around the teeth, tissue loss and eventually tooth loss. Despite the fact that periodontal disease in the pet population can be slowed by daily tooth brushing, most pet owners are not aware of this simple fact. The optimal approach would be to target the patient's inflammation response and slow the breakdown of structural elements in the gum tissue. ECPF-2, is a novel, specific, safe, water-soluble metalloprotease inhibitor that veterinary dentists and pet owners can use as an adjunct to current scaling and root planing therapies.LEARN ABOUT ECPF-2